🚀 VC round data is live in beta, check it out!
Vivos Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vivos and similar public comparables like CytoSorbents, Nortech Systems, Pulsenmore, Implanet and more.
Vivos Overview
About Vivos
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Founded
1994
HQ
Employees
1
Website
Financials (FY)
EV
$37M
Vivos Financials
Vivos reported last fiscal year revenue of $68K and negative EBITDA of ($3M).
In the same fiscal year, Vivos generated ($60K) in gross profit, ($3M) in EBITDA losses, and had net loss of ($3M).
Vivos P&L
In the most recent fiscal year, Vivos reported revenue of $68K and EBITDA of ($3M).
Vivos expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $68K | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($60K) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (87%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (4628%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (4629%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($3M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (4484%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vivos Stock Performance
Vivos has current market cap of $38M, and enterprise value of $37M.
Market Cap Evolution
Vivos' stock price is $0.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $37M | $38M | -2.9% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVivos Valuation Multiples
Vivos trades at 538.0x EV/Revenue multiple, and (11.6x) EV/EBITDA.
Vivos Financial Valuation Multiples
As of April 11, 2026, Vivos has market cap of $38M and EV of $37M.
Equity research analysts estimate Vivos' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vivos has a P/E ratio of (12.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38M | XXX | $38M | XXX | XXX | XXX |
| EV (current) | $37M | XXX | $37M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 538.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (11.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (11.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (615.6x) | XXX | XXX | XXX |
| P/E | — | XXX | (12.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (17.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vivos Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vivos Margins & Growth Rates
Vivos' revenue in the last fiscal year grew by 144%.
Vivos' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $3.1M for the same period.
Vivos Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 144% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (4628%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4026% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 515% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 4541% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vivos Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CytoSorbents | XXX | XXX | XXX | XXX | XXX | XXX |
| Nortech Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| Pulsenmore | XXX | XXX | XXX | XXX | XXX | XXX |
| Implanet | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroOne Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vivos M&A Activity
Vivos acquired XXX companies to date.
Last acquisition by Vivos was on XXXXXXXX, XXXXX. Vivos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vivos
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVivos Investment Activity
Vivos invested in XXX companies to date.
Vivos made its latest investment on XXXXXXXX, XXXXX. Vivos invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vivos
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vivos
| When was Vivos founded? | Vivos was founded in 1994. |
| Where is Vivos headquartered? | Vivos is headquartered in United States. |
| How many employees does Vivos have? | As of today, Vivos has over 1 employees. |
| Is Vivos publicly listed? | Yes, Vivos is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Vivos? | Vivos trades under RDGL ticker. |
| Who are competitors of Vivos? | Vivos main competitors are CytoSorbents, Nortech Systems, Pulsenmore, Implanet. |
| What is the current market cap of Vivos? | Vivos' current market cap is $38M. |
| What is the current revenue of Vivos? | Vivos' last fiscal year revenue is $68K. |
| What is the current EV/Revenue multiple of Vivos? | Current revenue multiple of Vivos is 538.0x. |
| Is Vivos profitable? | No, Vivos is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.